38975-44-9

Usage

Uses

Used in Pharmaceutical Industry:
1H-Purine-1-pentanoic acid, 2,3,6,7-tetrahydro-3,7-dimethyl-2,6-dioxois used as an active metabolite for the enhancement of blood flow and treatment of peripheral vascular disease. Its ability to increase erythrocyte flexibility and reduce blood viscosity contributes to improved circulation and reduced risk of blood clot formation.
Used in Peripheral Vascular Disease Treatment:
1H-Purine-1-pentanoic acid, 2,3,6,7-tetrahydro-3,7-dimethyl-2,6-dioxois used as a therapeutic agent for the treatment of peripheral vascular disease. Its role in inhibiting platelet aggregation and improving erythrocyte flexibility helps alleviate symptoms and complications associated with this condition.

InChI:InChI=1/C12H16N4O4/c1-14-7-13-10-9(14)11(19)16(12(20)15(10)2)6-4-3-5-8(17)18/h7H,3-6H2,1-2H3,(H,17,18)

Upstream product

• 83-67-0 theobromine / 
• 2067-33-6 5-bromopentanoic acid 

Downstream Products

• 1009086-36-5 C₃₅H₄₄N₆O₉ 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIODONTITIS AND RHEUMATOID ARTHRITIS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of periodontitis and rheumatoid arthritis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Immunosuppressive effects of 8-substituted xanthine derivatives

The invention relates to a novel use of 8 substituted xanthine derivatives for the manufacture of a medicament for the treatment of auto-immuno disorders. The invention relates in particular to the use of a xanthine derivative of general formula (I): wherein: R1, R2and R3are independently hydrogen, saturated or unsaturated aliphatic chains which may be straight or branched having 1 to 6 carbon atoms; X and Y are independently oxygen or sulfur; Z1is selected from the group comprising a thienyl; furanyl; cyclopentyl, phenyl or a substituted by Z2or unsubstituted phenyl; wherein Z2is selected from the group comprising phenyl; sulfonic acid; unsubstituted or N-substituted sulfonamide with substituents such as alkyl, aminoalkyl where the amino group may be substituted itself with lower alkyl groups bearing 1 to 4 carbon atoms; nitro; halogen substituted or unsubstituted amino group; aliphatic chain with 1 to 3 carbon atoms; halogenated aliphatic chain with 1 to 3 carbon atoms; aliphatic chain containing ether functions, acids, esters, amides, substituted or unsubstituted amines having 1 to 3 carbon atoms, nitro, sulfonamides or a combination of these functional groups with a maximum length of the chain of 12 atoms, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of auto-immuno disorders.